Physician profile
John C Hill
NPI 1174587588
$4,303.17
in general payments reported to CMS, 2019-2025
41 companies · $535 in 2025
The $535 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $335 · 2021: $294 · 2022: $153 · 2023: $962 · 2024: $1,104 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,345 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,345.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $256.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $939.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $468.45 | 2019-2025 | Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $272.38 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $271.16 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $256.00 | 2024 | |
| Amgen INC. | $195.31 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $160.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $152.32 | 2019-2024 | Rexulti |
| Exact Sciences Corporation | $139.94 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $138.29 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.81 | 2019-2024 | Xifaxan |
| Pfizer INC. | $108.09 | 2019-2025 | |
| Lundbeck LLC | $107.92 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.10 | 2019-2025 | Jardiance |
| Acadia Pharmaceuticals INC | $101.97 | 2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $90.04 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $80.65 | 2019 | |
| Csl Behring | $62.01 | 2025 | Hizentra |
| Genentech USA, INC. | $56.87 | 2019 | |
| Abbvie INC. | $48.38 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $40.73 | 2023-2025 | Gvoke Hypopen |
| Janssen Biotech, INC. | $34.42 | 2022 | |
| Edwards Lifesciences Corporation | $33.93 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Idorsia Pharmaceuticals US INC | $32.66 | 2023-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $24.38 | 2019 | |
| Dynavax Technologies Corporation | $22.76 | 2025 | Heplisav-B |
| Lucid Diagnostics INC. | $21.73 | 2024 | |
| Dexcom, INC. | $20.36 | 2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $19.65 | 2023 | |
| Ucb, INC. | $18.11 | 2024 | Nayzilam |
| Krystal Biotech INC | $18.11 | 2025 | Vyjuvek |
| Vanda Pharmaceuticals INC. | $17.22 | 2025 | Fanapt |
| Kyowa Kirin, INC. | $16.99 | 2025 | |
| Axsome Therapeutics, INC. | $15.90 | 2025 | Auvelity |
| Abiomed | $15.50 | 2024 | Impella |
| Avanir Pharmaceuticals, INC. | $15.45 | 2019 | |
| Abbott Laboratories | $14.55 | 2023 | Freestyle Libre 3 |
| Scilex Pharmaceuticals INC. | $14.54 | 2020 | |
| Smith+Nephew, INC. | $13.25 | 2024 | Pico |
| Merck Sharp & Dohme LLC | $11.71 | 2019 | |
| Allergan, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.